Hurler syndrome

REGENXBIO ($RGNX) investors have until April 14, 2026 to join securities class action over allegedly misleading RGX-111 trial statements.

ProQR Therapeutics expands pipeline with lead program AX-0810 targeting H1 2026 data readout in biliary atresia, supported by three additional programs advancing through 2027.

REGENXBIO faces securities class action alleging false statements about RGX-111 gene therapy. Lead plaintiff deadline April 14, 2026.

Securities lawsuit alleges REGENXBIO made misleading statements about RGX-111 gene therapy. Investors have until April 14, 2026 to file.

Rosen Law Firm recruits lead plaintiffs for securities class action against REGENXBIO over alleged false statements regarding RGX-111 gene therapy trial data. Lead plaintiff deadline: April 14, 2026.

Rosen Law Firm recruits investors for securities class action against REGENXBIO over alleged RGX-111 gene therapy misstatements. Lead plaintiff deadline: April 14, 2026.

Securities lawsuit filed against $RGNX alleging misleading statements about RGX-111 gene therapy. Eligible investors must act before April 14, 2026 deadline.

Securities lawsuit filed against $RGNX for allegedly misleading investors about RGX-111 gene therapy efficacy and safety. Lead plaintiff deadline April 14, 2026.

REGENXBIO faces class action over alleged misleading statements about RGX-111 gene therapy. Investors who bought stock between February 2022 and January 2026 may seek compensation.

REGENXBIO faces class action lawsuit over RGX-111 gene therapy trial disclosures. Lead plaintiff deadline is April 14, 2026.

REGENXBIO faces securities lawsuit alleging misleading statements about RGX-111 gene therapy. Lead plaintiff deadline extended to April 14, 2026.

Class action lawsuit filed against REGENXBIO for allegedly making false statements about gene therapy safety and efficacy while withholding adverse trial information from investors.

REGENXBIO faces class action lawsuit over allegedly false safety disclosures for gene therapy RGX-111. FDA clinical hold triggered 17.8% stock drop after adverse trial findings.

REGENXBIO faces securities lawsuit over alleged false statements about gene therapy safety. Investors have until April 14 deadline to join class action after FDA clinical hold.

Law firm sues REGENXBIO for allegedly hiding safety concerns about gene therapy RGX-111. Stock dropped 17.8% after FDA clinical hold due to tumor in trial participant.